Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease caused by the selective and progressive death of motor neurons (MNs). Understanding the genetic and molecular factors influencing ALS survival is crucial for disease management and therapeutics. In this study, we introduce a deep learning-powered genetic analysis framework to link rare noncoding genetic variants to ALS survival. Using data from human induced pluripotent stem cell (iPSC)-derived MNs, this method prioritizes functional noncoding variants using deep learning, links cis-regulatory elements (CREs) to target genes using epigenomics data, and integrates these data through gene-level burden tests to identify survival-modifying variants, CREs, and genes. We apply this approach to analyze 6,715 ALS genomes, and pinpoint four novel rare noncoding variants associated with survival, including chr7:76,009,472:C>T linked to CCDC146. CRISPR-Cas9 editing of this variant increases CCDC146 expression in iPSC-derived MNs and exacerbates ALS-specific phenotypes, including TDP-43 mislocalization. Suppressing CCDC146 with an antisense oligonucleotide (ASO), showing no toxicity, completely rescues ALS-associated survival defects in neurons derived from sporadic ALS patients and from carriers of the ALS-associated G4C2-repeat expansion within C9ORF72. ASO targeting of CCDC146 may be a broadly effective therapeutic approach for ALS. Our framework provides a generic and powerful approach for studying noncoding genetics of complex human diseases.
Competing Interest Statement
M.P.S. is a co-founder and the scientific advisory board member of Personalis, Qbio, January, SensOmics, Filtricine, Akna, Protos, Mirvie, NiMo, Onza, Oralome, Marble Therapeutics and Iollo. He is also on the scientific advisory board of Danaher, Genapsys, and Jupiter. J.K.I. is a co-founder and a scientific advisory board member of AcuraStem, Inc. and Modulo Bio, a scientific advisory board member of Synapticure and Vesalius Therapeutics. J.K.I. is also an employee of BioMarin Pharmaceutical. The remaining authors declare no competing interests.
Funding Statement
This work was supported by NIH (CEGS 5P50HG007735 to M.P.S., R01NS131409 and R01NS097850 to J.K.I.), Wellcome Trust (216596/Z/19/Z to J.C.-K.), NIHR (NF-SI-0617-10077 to P.J.S.), Motor Neurone Disease (MND) Association (899-792 and 913-792 to C.H., S.G. and J.C.-K.), and John Douglas French Alzheimer's Foundation (to J.K.I.). We also acknowledge support from the MND Association Fellowship (2323-799) and the Kingsland Fellowship (to T.M.), the NIHR Sheffield Biomedical Research Centre for Translational Neuroscience (IS-BRC-1215-20017), and the NIHR Sheffield Clinical Research Facility.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the South Sheffield Research Ethics Committee. Also, this study followed study protocols approved by Medical Ethical Committees for each of the participating institutions. Written informed consent was obtained from all participating individuals. All methods were performed in accordance with relevant national and international guidelines and regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The epigenome and transcriptome profiling data of iPSC-derived motor neurons used in the ABC model and NeuroNet are available at encodeproject.org with the following link: https://www.encodeproject.org/publications/de19555b-a49f-471c-bfbc-be3b628fe9bf/. NeuroNet variant effect scores can be downloaded at https://doi.org/10.6084/m9.figshare.25444534. The Project MinE WGS data are accessible upon application approval (https://www.projectmine.com/research/data-sharing/). The AnswerALS WGS and RNA-seq data are available upon request approval (https://dataportal.answerals.org/home).
https://www.encodeproject.org/publications/de19555b-a49f-471c-bfbc-be3b628fe9bf/
https://doi.org/10.6084/m9.figshare.25444534
